Introduction Oesophageal adenocarcinoma presents an ever increasing challenge to the NHS, with rising incidence and poor overall survival. There are few robust biomarkers available for this disease – either for detection or stratification. Barrett’s Oesophagus, a precursor to adenocarcinoma, is common. In the non-dysplastic setting, few patients will progress to cancer. There are no current biomarkers to aid in this stratification process. Aims To assess the role of methylation biomarkers in the context of diagnosis of adenocarcinoma and their role in tumour biology. To provide a methylation stratification tool in the identification of high risk non-dysplastic Barrett’s Oesophagus. Methods Genome wide methylation assessment was performed with validation using bisulphite pyrosequencing on carefully selected tissues to reveal novel methylation biomarkers Results Methylation of TRIM15, has been shown to be a robust biomarker in disease identification and has a role in tumour biology. OR3A4, a long none coding RNA, has been identified as a way to reliably risk stratify the non-dysplastic Barrett’s patient and forms the first biomarker of this kind. Conclusions Methylation biomarkers play a key role in disease identification and risk of cancer development. They also appear to play a role in tumour biology.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:694728 |
| Date | January 2016 |
| Creators | Dilworth, Mark |
| Publisher | University of Birmingham |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
| Source | http://etheses.bham.ac.uk//id/eprint/6912/ |
Page generated in 0.0021 seconds